(Total Views: 661)
Posted On: 03/03/2021 12:58:12 AM
Post# of 148878
Interesting that "Posession of Material information" negative or positive, which could influence share price, must be disclosed within 4 days.
This suggests that our CEO has not seen the unblinded data. Maybe the s/c data went directly from the DSMC to the FDA?
Regardless, IMO, it would still be the "silence" which leads us to expect the results are great. If not great, the FDA would have acted to let the info out
Unless however, if the data for the Primary Endpoint was good but not good enough for Stat Significance & they're working out an EUA based on overall data. IMO, this is not the case.
This suggests that our CEO has not seen the unblinded data. Maybe the s/c data went directly from the DSMC to the FDA?
Regardless, IMO, it would still be the "silence" which leads us to expect the results are great. If not great, the FDA would have acted to let the info out
Unless however, if the data for the Primary Endpoint was good but not good enough for Stat Significance & they're working out an EUA based on overall data. IMO, this is not the case.
(1)
(0)Scroll down for more posts ▼
